South Gibson Star-Times

May 14, 2019

The South Gibson Star-Times serves the towns of Haubstadt, Owensville and Fort Branch.

Issue link: https://www.ifoldsflip.com/i/1116193

Contents of this Issue

Navigation

Page 22 of 23

B-10 Opinion Tuesday, May 14, 2019 South Gibson Star-Times ECONOMY Continued from page 9 MEDICATION Continued from page 9 Second, tame out-of-con- trol spending. Politicians once took their responsibil- ity to be sensible stewards of the national purse seriously, but profligacy has since be- come a way of life on both sides of the aisle. The tre- mendous amount of debt we're accumulating will sad- dle future generations with higher taxes and less oppor- tunity. And if we don't attack this problem when our economy is so strong, when will we? So let's act — and shore up the tremendous gains we've seen so far. Ed Feulner is founder of The Heritage Foundation (www.heritage.org). to the attempts to confiscate the profits that flow from the successes. Your retire- ment fund's money manag- er would be negligent if he failed to pay attention to the companies' profits. If that American invest- ment dries up, who will de- velop medicines and medi- cal technology in the future? Canada? We can buy medi- cine much cheaper there than in our own country. Why not just outsource the pharmaceutical industry, including all investment, in- novation, regulatory compli- ance and risk-taking to Can- ada? That ought to make the A ARP happy. The truth, of course, is that Canada is a parasite on American investment and innovation. Most, if not all the cheap medicine that you can buy in Canada or Mex- ico is produced in the U.S. and would never exist if not for American investment, which in turn would not ex- ist without American profits. It's annoying that foreign countries can piggyback on our pharmaceutical indus- try, not only on American producers but on American consumers who pay the pric- es that sustain the research and development, including regulatory compliance, by the American industry. But make no mistake: parasites can't replace the U.S. phar- maceutical industry. And why would they want to? If you think it's far-fetched that U.S. pharmaceutical companies would walk away from the market, consider what's happening in antibi- otics. There's been very lit- tle antibiotic research by the major drug companies in recent years, not because they're discouraged by the science, but because it's al- most impossible to make money on antibiotics once you develop them. There are 42 antibiotics in human trials now, according to Businessweek magazine, but "only four come from the largest 50 drug companies." Yet the smaller firms are fi- nancially ill equipped to sur- vive the regulatory approval process, which can stretch nearly 20 years into the fu- ture. We are presiding over the death of U.S. antibiotic research and development precisely when we need it most urgently. Chickens are coming home to roost after decades of casual, promiscuous mis- use of common antibiotics. Pathogens have developed resistance to entire class- es of antibiotics. The conse- quences are grim, according to the Centers for Disease Control. It undermines "our ability to fight infectious dis- eases and manage the infec- tious complications common in vulnerable patients under- going chemotherapy for can- cer, dialysis for renal failure, and surgery." Pharmaceutical corpora- tions are not funded by San- ta Claus. They eventually make money from consum- ers, if all goes well. But ini- tial investment comes from shareholders who can pick up the phone at any time to move their money into Gen- eral Motors or Budweiser. Shares for antibiotic manu- facturer Melinta Therapeu- tics have fallen 94 percent since early 2018. Achaogen filed for bankruptcy last month. Achaogen, you may re- call, is the company that de- veloped an antibiotic that kills deadly carbapenem-re- sistant enterobacteriace- ae (CRE) in the test tube. The company got part-way through the regulatory gauntlet. Despite its feats of scientific research, the cor- poration couldn't hang on until profitability. Its assets will be auctioned off next month. Corporations are not indestructible. I have no human right to antibiotics, or to any other pharmaceuticals, or to an- ybody's involuntary medi- cal services. But my right to freely contract for anti- biotics and medical exper- tise has been lifesaving, as recently as last year. I am hoping for more greed, not less, in the pharmaceutical industry. TRADE UP TRADE IN GET UP TO $ 500 OVER KBB INSTANT CASH OFFER ON A NEW OR USED TOYOTA ++ ++Your vehicle's final trade-in value is set by the dealer after inspection and is affected by vehicle condition, mileage, vehicle history and repairs and other factors. Purchase excludes tax, title, license and $199 dealer fee. *All new vehicles: savings off MSRP. In-stock vehicles only. College Grad and military rebates are not included in offers. Purchase excludes tax, title, license and $199 dealer fee. APR offers are in lieu of manufacturer's rebates with approved credit. New 2019 Camry SE: #1910324 MSRP $29,249 $2,122 Kenny Kent Savings and $1,000 Manufacturer's Rebate. †Toyota Care: Covers normal factory scheduled service for 2 years or 25,000 miles, whichever comes first. See Toyota dealer for details and exclusions. Valid only in the continental U.S. and Alaska. All offers expire May 31, 2019. 5600 Division Street, Evansville, IN • 1-800-321-5368 • www.KennyKentToyota.com #1910324 New 2019 Camry SE SAVE $ 3,122 * Next-Level Safety at No Extra Cost FFER OR OR OR OR A ++ ++ 00 Division Street, Evansville, IN • 1-800-321-5368 • www 00 Division Street Evansville IN 1 800 321 5368 www #19 #19103 03 03 10 24 24 24 Letter to the Editor Indiana teachers deserve more I am profoundly disappointed that Governor Holcomb deliberately disre- garded the calls of Indiana teachers for better funding for public schools and higher wages. Their work is in- credibly important to our community and we know the value teachers cre- ate in each and every child they touch. For the governor to sign a budget that does not include an across-the-board raise for teachers is shameful. Our educators are professionals, of- ten with more than one degree, yet we don't even pay them enough to en- sure they won't have to work two jobs. Teacher pay in Indiana is the slow- est-growing in the nation. Dead last. The average teacher salary in Indi- ana has been on a downward slide for nearly two decades, when adjusted for inflation. With the cost of living ris- ing year after year, we're reaching a point where our teachers simply can't afford to teach. It's no wonder we can't retain or at- tract the best educators to our public schools. Lawmakers have largely ig- nored the growing teacher shortage crisis because they refuse to belief our educators are underpaid. It's about re- spect and Holcomb, like Republican leaders before him, just doesn't seem to respect educators. In a recent ranking of the best schools in Indiana by U.S. News & World Report, all the highly ranked schools were public schools, not pri- vate schools. We need bold action on this issue. When will Holcomb and GOP lead- ers put Hoosier children in public schools first? Hoosiers deserve an- swers, Governor. It's time to raise their pay. Dr. Jim Isaacs Oakland City Retired Gibson Southern Principal OCS FINE ARTS NIGHT SUBSCRIBE TODAY! We're not afraid to shed some light on the truth. 812-753-3553 South Gibson Annie Lucas plays "Novellette" on her clarinet Students participate in marble painting. Woodwind ensemble shows their skills. Brass ensemble performs a musical number. Leon Viehe plays "It's a Small World." Brooklyn Cashburn sings and plays "The Climb." Aaron Lara sings "Puff the Magic Dragon." Asher Ping sings. Kamryn Burger sings.

Articles in this issue

Links on this page

Archives of this issue

view archives of South Gibson Star-Times - May 14, 2019